Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Completed NCT05772546

Avatrombopag vs. Placebo for CIT in GI Malignancies

Conditions: Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE2

Enrollment: 49

Sponsor: Hanny Al-Samkari, MD

Location: University of Miami Sylvester Comprehensive Cancer Center Miami Florida

Summary

The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving cytotoxic chemotherapy. The names of the study drugs involved in this study are: * Avatrombopag (a thrombopoietin receptor agonist) * Matching placebo

Eligibility Criteria

Inclusion Criteria: * A diagnosis of persistent chemotherapy-induced thrombocytopenia, as defined by a platelet count of \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05772546). StuddyBuddy aggregates publicly available trial information.